MSD’s sac-TMT meets primary endpoints in Phase III endometrial cancer trial

MSD’s sac-TMT is being developed in collaboration with Kelun-Biotech in a range of cancer indications. MSD’s sac-TMT is being developed in collaboration with Kelun-Biotech in a range of cancer indications. MSD said that TroFuse-005 is the first global Phase III trial to demonstrate statistically significant improvement in both OS and PFS compared to chemotherapy for these patients and the first and only ADC to do so for patients with endometrial cancer in this setting. Credit: HJBC / Shutterstock.com MSD’s TROP2-directed antibody-drug conjugate (ADC), sac-TMT, has shown benefit in both overall survival (OS) and progression-free survival (PFS) in a Phase III…

Source: Clinical Trials Arena